Abstract:Chronic inflammation can lead to the development of many diseases, including cancer. Inflammatory bowel disease (IBD) that includes both ulcerative colitis (UC) and Crohnmp's disease (CD) are risk factors for the development of colorectal cancer (CRC). Many cytokines produced primarily by the gut immune cells either during or in response to localized inflammation in the colon and rectum are known to stimulate the complex interactions between the different cell types in the gut environment resulting in acute inflammation. Subsequently, chronic inflammation, together with genetic and epigenetic changes, have been shown to lead to the development and progression of CRC. Various cell types present in the colon, such as enterocytes, Paneth cells, goblet cells, and macrophages, express receptors for inflammatory cytokines and respond to tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), IL-6, and other cytokines. Among the several cytokines produced, TNF-α and IL-1β are the key pro-inflammatory molecules that play critical roles in the development of CRC. The current review is intended to consolidate the published findings to focus on the role of pro-inflammatory cytokines, namely TNF-α and IL-1β, on inflammation (and the altered immune response) in the gut, to better understand the development of CRC in IBD, using various experimental model systems, preclinical and clinical studies. Moreover, this review also highlights the current therapeutic strategies available (monotherapy and combination therapy) to alleviate the symptoms or treat inflammation-associated CRC by using monoclonal antibodies or aptamers to block pro-inflammatory molecules, inhibitors of tyrosine kinases in the inflammatory signaling cascade, competitive inhibitors of pro-inflammatory molecules, and the nucleic acid drugs like small activating RNAs (saRNAs) or microRNA (miRNA) mimics to activate tumor suppressor or repress oncogene/pro-inflammatory cytokine gene expression.

Ulcerative Colitis-Induced Colorectal Carcinoma: A Deleterious Concatenation

Inflammatory Bowel Disease and Colorectal Cancer

Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives

[Ulcerative colitis-associated carcinogenesis : An update]

Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications

Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention

Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management

Colorectal cancer in inflammatory bowel disease: a review of the role of gut microbiota and bacterial biofilms in disease pathogenesis

Colorectal cancer in inflammatory bowel disease: review of the evidence

Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis

Ulcerative colitis and colon cancer: Biology and surveillance

Inflammatory Bowel Disease and Colorectal Cancer: Epidemiology, Etiology, Surveillance, and Management

Inflammatory bowel disease and carcinogenesis

Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines

Role of Inflammation in the Development of Colorectal Cancer

Overcoming cancer risk in inflammatory bowel disease: new insights into preventive strategies and pathogenesis mechanisms including interactions of immune cells, cancer signaling pathways, and gut microbiota

Colorectal Cancer in Patients with Inflammatory Bowel Disease: The True Impact of the Risk

Incident Colorectal Cancer in Inflammatory Bowel Disease

Inflammatory colonic carcinogenesis: A review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis

Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy

Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota